Posts Tagged ‘leukemia’

Insights from CGTW16 – Part 1: Cell Manufacturing Best Practices

Author: Guest, 11/17/16

Amin Adibi is a biomedical engineer and a research assistant at the University of British Columbia. His areas of interest include cell manufacturing and bioprocess optimization, clinical translation of cellular therapies, health outcomes and cost-effectiveness modelling. Amin has an MSc degree from University of Calgary, where he focused on developing adjuvant MSC-based therapies for brain…Read more

ISSCR final day – Not just one hit… finding combinations in cancer

Author: David Kent, 07/18/16

During the morning plenary session on the final day of ISSCR, we were treated to a delightful mix of basic and translational science as well as a riveting public policy lecture from Alta Charo. The session was all about disease modeling and stem cells and the highlight talk for me was from Guy Sauvageau, who…Read more

Update from the Clinic: April

Author: Mark Curtis, 05/25/15

. Welcome to your Update from the Clinic for the month of April. Mesenchymal stem cells took a hit as Athersys’ MultiStem came up short, missing its primary endpoint in a Phase 2 study investigating the cells for ischemic stroke. Juno Therapeutics continues to turn heads with its Phase 1/2 data in blood cancers. NeoStem,…Read more

By all means, target the CSCs – but leave the normal stem cells out of it!

Author: Sara M. Nolte, 05/19/15

. I’ve spent a number of posts going on and on about how targeting cancer stem cells (CSCs) is the next big thing for cancer therapies, and how important it is that we study and learn all we can about them (know your enemy, right?). All of this has probably left you with at least…Read more

Right turn: If you had leukemia or lymphoma, what would you want to know?

Author: Lisa Willemse, 04/25/14

> Julia Pon is a MD/PhD student at the University of British Columbia with an interest in blood cancer. Like many before her, she noticed that the kind of information that is shared with cancer patients is different than what medical students are taught about the disease: one set of information focuses on symptoms and…Read more

Regenerative Medicine Deal Review

Author: Mark Curtis, 10/17/13

. Welcome to the first Regenerative Medicine Deal Review, an overview of recent licensing, partnering, and financing activity all exclusively in the regenerative medicine and cell therapy industries. Like my first post ‘Update from the Clinic’, this piece is intended to be a regular contribution that can be used for informational purposes to stay apprised…Read more

Preliminary success in blood stem cell gene therapy

Author: David Kent, 08/12/13

. Last month, two studies were published in Science from Luigi Naldini’s group on correcting disease-associated mutations in patient’s stem cells. The two diseases, Wiskott-Aldrich Syndrome (WAS) and Metachromatic Leukodystrophy, are sometimes treated with bone marrow transplantation, which relies on identification of matched donors and risks severe complications through graft vs. host disease and lifelong immunosuppression. Using a patient’s own…Read more

Why research? The personal foundations of cancer research

Author: Sara M. Nolte, 05/30/13

. My interest (maybe even fascination) in cancer began when I was six years old: I was diagnosed with acute myeloblastic leukemia (a cancer of white blood cells), and am now able to say that I am a childhood cancer survivor. After realizing that I was no longer interested in going to medical school to…Read more

Master debaters have bone (marrow) to pick at StemCellTalks Toronto

Author: Stacey Johnson, 03/27/13

I’ve always had an interest in the science of bone marrow transplants, ever since my nephew, Simon, was diagnosed with aplastic anemia at the age of two.  Although it was a traumatic time for his parents and extended family, the story has a happy ending. His four-year-old brother was a bone marrow match and the…Read more

Till & McCulloch Meetings 2012: Lessons to learn from leukemic stem cells

Author: Guest, 05/07/12

  by Alexey Bersenev The first plenary session of the Till & McCulloch Meetings was dedicated to cancer stem cells. John Dick opened the session by asking a question: “Stem cells in cancer: do they matter?” He is always ahead of time, very precise and innovative and I think cancer stem cell researchers can learn…Read more